Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Haplo-HCT shows viability in DLBCL

Dreger P et al. Blood Adv. 2019 Feb 12;3(3):360-9

Key clinical point: For patients with diffuse large B-cell lymphoma (DLBCL) who need allogeneic hematopoietic cell transplantation (allo-HCT), a haploidentical family member could be a viable donor.

Major finding: The 3-year OS after haploidentical HCT (haplo-HCT) was 38%.

Study details: A retrospective study involving 1,438 patients with DLBCL.

Disclosures: The study was funded by the Center for International Blood & Marrow Transplant Research (CIBMTR) and the European Society for Blood and Marrow Transplantation. CIBMTR is supported by grants from the U.S. government and the pharmaceutical industry. The authors reported having no competing financial interests.


Dreger P et al. Blood Adv. 2019 Feb 12;3(3):360-9.